Investment Rating - Industry Rating: Outperform the market (maintained rating) [6] Core Viewpoints - The report maintains a positive outlook on the AI industry as a key investment theme for the year, anticipating that 2025 may become a pivotal year for domestic AI infrastructure competition and application development [3][19] - The report emphasizes the importance of monitoring AI industry dynamics and investment opportunities in AI applications, as well as the potential for growth in the satellite internet sector due to recent domestic developments [3][20] Summary by Sections 1. Artificial Intelligence and Digital Economy - Key recommendations include: - Optical modules & optical devices: Focus on companies like Zhongji Xuchuang, Xinyi Sheng, Tianfu Communication, and Yuanjie Technology [4][22] - Switches and server PCBs: Recommended companies include Hudian Co., ZTE, and Unisplendour [4][22] - Low valuation, high dividend companies in cloud and computing IDC resources: China Mobile, China Telecom, and China Unicom [4][22] - AIDC & cooling solutions: Key recommendations include Yingweike and Runze Technology [4][22] - AIGC applications/edge computing: Focus on companies like Guohua Communication and Meige Intelligent [4][22] 2. Offshore Wind and Submarine Cables - Key recommendations for submarine cables: Hengtong Optic-Electric, Zhongtian Technology, and Oriental Cable [5][23] - Focus on recovery and concentration of leading companies in overseas markets, with recommendations including Huace Navigation and Weisheng Information [5][23] 3. Satellite Internet and Low-altitude Economy - Accelerated development of low-orbit satellites and low-altitude economy, with key recommendations including Huace Navigation and Haige Communication [6][24] - Suggested companies to watch include Chengchang Technology and Zhenlei Technology [6][24] 4. Industry Performance Review - The communication sector rose by 5.06% during the week of June 3-6, outperforming the CSI 300 index by 4.18 percentage points [25] - Notable individual stock performances included Huamai Technology and Zhongjia Bochuang, both showing significant gains [26][29]

Market Review - The A-share market exhibited a narrow fluctuation pattern in May, with the average monthly trading volume remaining around 1.2 trillion yuan, consistent with the previous month [3][9] - The pharmaceutical and new consumption sectors showed strong performance, with the highest consecutive trading limits primarily among ST stocks [3][9] - The margin trading balance showed a slow increase in May, but the net inflow of main funds slowed down in the latter half of the month [17][19] Policy Dynamics - A comprehensive set of financial policies was introduced to stabilize the market and expectations, including a 0.5 percentage point reduction in the reserve requirement ratio, expected to provide approximately 1 trillion yuan in long-term liquidity [24][25] - The "Digital China Construction 2025 Action Plan" aims for the digital economy's core industry value-added to exceed 10% of GDP by the end of 2025, with a computing power scale exceeding 300 EFLOPS [3][20] - The introduction of the "Stablecoin Regulation" in Hong Kong marks a significant step in promoting financial innovation while maintaining stability in the digital asset sector [3][20] Industry Trends - The evolution of large models towards multimodal capabilities is highlighted, with significant advancements in AI technologies from companies like ByteDance, Alibaba, and Tencent [3][32] - The Ministry of Industry and Information Technology emphasized accelerating the development of 5G-A and 6G technologies, indicating a strong push towards advanced telecommunications [3][32] - The "Intelligent Transformation Implementation Plan for the Pharmaceutical Industry (2025-2030)" aims to enhance the digital transformation of the pharmaceutical sector, focusing on smart drug development and production processes [29][32]

Investment Rating - The investment rating for the company is "Buy" with an expected relative return of over 20% within the next six months [11]. Core Insights - The company reported a revenue of 530 million yuan in Q1 2025, representing a year-over-year increase of 46.3%. The gross margin was 41.7%, up by 2.9 percentage points year-over-year. Non-GAAP net profit reached 8.6 million yuan, marking a return to profitability [2]. - The total shipment of LiDAR units in Q1 2025 was 195,818 units, a year-over-year increase of 231.3%, with ADAS LiDAR shipments accounting for 146,087 units, up 178.5% year-over-year [2]. - The company has established ADAS partnerships with 23 OEMs globally, covering over 120 vehicle models, and has made significant progress in both domestic and international markets [2][3]. - The company anticipates strong growth in 2025, projecting revenues between 3 billion to 3.5 billion yuan and LiDAR deliveries of 1.2 to 1.5 million units, with 200,000 units expected in the robotics sector [4]. Summary by Sections Q1 2025 Performance Overview - Revenue was 530 million yuan, with a year-over-year growth of 46.3% - Gross margin stood at 41.7%, an increase of 2.9 percentage points year-over-year - Non-GAAP net profit was 8.6 million yuan, indicating a return to profitability [2] Business Development - The company has secured ADAS partnerships with 23 OEMs globally, involving over 120 vehicle models - New POC projects with top-tier OEMs in Japan and Europe are underway, with several completed in Q1 2025 - Domestic partnerships include new models from various car manufacturers [2][3] Robotics Sector - The company plans to supply 300,000 units of the JT series LiDAR to a partner in the lawn mowing sector within the next year - Collaborations in the Robotaxi and unmanned delivery sectors are progressing towards commercial operations [3] Production Capacity Expansion - A new production line is set to commence operations in Q3 2025, with an expected annual output of 2 million units by the end of the year - A new factory in Southeast Asia is planned to be operational by late 2026 or early 2027 [3] Future Outlook - The company expects to maintain strong growth momentum in 2025, with revenue projections of 3 billion to 3.5 billion yuan and LiDAR deliveries of 1.2 to 1.5 million units [4] - The company is well-positioned to benefit from the growth of the autonomous driving industry and increasing penetration of L2+/L3 technologies [4]

Quantitative Factors and Construction Methods Factor Name: BP (Book-to-Price Ratio) - **Construction Idea**: Measures the valuation of a stock by comparing its book value to its market value [13] - **Construction Process**: - Formula: $ BP = \frac{\text{Current Book Value}}{\text{Current Market Value}} $ [13] Factor Name: BP Three-Year Percentile - **Construction Idea**: Evaluates the relative valuation of a stock over the past three years [13] - **Construction Process**: - Formula: BP Three-Year Percentile = Percentile rank of the current BP within the last three years [13] Factor Name: Quarterly EP (Earnings-to-Price Ratio) - **Construction Idea**: Measures the profitability of a stock relative to its market price [13] - **Construction Process**: - Formula: $ \text{Quarterly EP} = \frac{\text{Quarterly Net Profit}}{\text{Net Assets}} $ [13] Factor Name: Quarterly EP One-Year Percentile - **Construction Idea**: Tracks the relative profitability of a stock over the past year [13] - **Construction Process**: - Formula: Quarterly EP One-Year Percentile = Percentile rank of the current Quarterly EP within the last year [13] Factor Name: Quarterly SP (Sales-to-Price Ratio) - **Construction Idea**: Measures the revenue generation capability of a stock relative to its market price [13] - **Construction Process**: - Formula: $ \text{Quarterly SP} = \frac{\text{Quarterly Revenue}}{\text{Net Assets}} $ [13] Factor Name: Quarterly SP One-Year Percentile - **Construction Idea**: Tracks the relative revenue generation capability of a stock over the past year [13] - **Construction Process**: - Formula: Quarterly SP One-Year Percentile = Percentile rank of the current Quarterly SP within the last year [13] Factor Name: Small Market Cap - **Construction Idea**: Captures the size effect by focusing on smaller companies [13] - **Construction Process**: - Formula: $ \text{Small Market Cap} = \log(\text{Market Capitalization}) $ [13] Factor Name: 1-Month Reversal - **Construction Idea**: Captures the short-term reversal effect in stock prices [13] - **Construction Process**: - Formula: $ \text{1-Month Reversal} = \text{Cumulative Return over the Last 20 Trading Days} $ [13] Factor Name: Fama-French Three-Factor 1-Month Residual Volatility - **Construction Idea**: Measures the idiosyncratic risk of a stock based on the Fama-French three-factor model [13] - **Construction Process**: - Formula: $ \text{Residual Volatility} = \text{Standard Deviation of Residuals from Fama-French Three-Factor Regression over the Last 20 Trading Days} $ [13] --- Factor Backtesting Results IC Performance - **BP**: Weekly IC = -4.17%, Monthly IC = 0.88%, Yearly IC = 1.86%, Historical IC = 2.19% [9] - **BP Three-Year Percentile**: Weekly IC = -1.08%, Monthly IC = -0.99%, Yearly IC = 2.58%, Historical IC = 1.58% [9] - **Quarterly EP**: Weekly IC = 2.10%, Monthly IC = -0.48%, Yearly IC = -0.46%, Historical IC = 1.18% [9] - **Quarterly EP One-Year Percentile**: Weekly IC = 4.23%, Monthly IC = 3.81%, Yearly IC = 0.98%, Historical IC = 1.73% [9] - **Quarterly SP**: Weekly IC = 0.79%, Monthly IC = 0.93%, Yearly IC = 0.53%, Historical IC = 0.74% [9] - **Quarterly SP One-Year Percentile**: Weekly IC = 4.80%, Monthly IC = 2.82%, Yearly IC = 2.87%, Historical IC = 1.83% [9] - **Small Market Cap**: Weekly IC = 10.49%, Monthly IC = 8.17%, Yearly IC = 3.61%, Historical IC = 2.05% [9] - **1-Month Reversal**: Weekly IC = 7.22%, Monthly IC = 1.22%, Yearly IC = 3.40%, Historical IC = 2.22% [9] - **Fama-French Three-Factor 1-Month Residual Volatility**: Weekly IC = 3.60%, Monthly IC = 1.11%, Yearly IC = 3.49%, Historical IC = 2.48% [9] Excess Return Performance (Long-Only Portfolio) - **BP**: Weekly Excess Return = -0.83%, Monthly Excess Return = -1.04%, Yearly Excess Return = 3.02%, Historical Cumulative Excess Return = 28.90% [11] - **BP Three-Year Percentile**: Weekly Excess Return = -0.58%, Monthly Excess Return = -1.51%, Yearly Excess Return = 0.97%, Historical Cumulative Excess Return = -3.21% [11] - **Quarterly EP**: Weekly Excess Return = 0.57%, Monthly Excess Return = 1.10%, Yearly Excess Return = 1.44%, Historical Cumulative Excess Return = 30.83% [11] - **Quarterly EP One-Year Percentile**: Weekly Excess Return = -0.01%, Monthly Excess Return = 0.51%, Yearly Excess Return = 3.23%, Historical Cumulative Excess Return = 34.69% [11] - **Quarterly SP**: Weekly Excess Return = -0.01%, Monthly Excess Return = 0.49%, Yearly Excess Return = 0.70%, Historical Cumulative Excess Return = -2.69% [11] - **Quarterly SP One-Year Percentile**: Weekly Excess Return = 0.09%, Monthly Excess Return = 1.25%, Yearly Excess Return = 7.91%, Historical Cumulative Excess Return = 2.23% [11] - **Small Market Cap**: Weekly Excess Return = 0.96%, Monthly Excess Return = 2.76%, Yearly Excess Return = 18.31%, Historical Cumulative Excess Return = 62.57% [11] - **1-Month Reversal**: Weekly Excess Return = 0.83%, Monthly Excess Return = 0.76%, Yearly Excess Return = 3.54%, Historical Cumulative Excess Return = 1.57% [11] - **Fama-French Three-Factor 1-Month Residual Volatility**: Weekly Excess Return = 0.28%, Monthly Excess Return = 0.75%, Yearly Excess Return = 8.69%, Historical Cumulative Excess Return = 18.67% [11]

策略报告 | 投资策略 行业比较周报 证券研究报告 中美会谈下，自主可控板块的节奏与机会 核心结论：6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实 事求是看待取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访 华。双方经贸协商未完待续，自主可控仍是长期逻辑。自主可控的第一个逻 辑是国家政策多年布局下的积累；自主可控的第二个逻辑是国产替代。穿透 到二级行业，短期可以关注估值处于低位的方向，中期关注产业节奏。估值 方面，前期估值处于低位的板块主要为军工、医药、电子；产业节奏方面， 军工→信创→医药→先进制造。 中美关税会谈破冰后，双方经贸协商未完待续，自主可控仍是长期逻辑。5 月 12 日，中美双方发布《中美日内瓦经贸会谈联合声明》，中美双方关税 中枢回落，后续或仍有多轮协商。一方面，参考 2018 年-2020 年中美经贸谈 判，总共经历了十三轮高级别磋商，历时近两年才签署第一阶段经贸协议。 6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实事求是看待 取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访华。 另一方面，4 月中旬美方发起的 232 调查和 301 调查仍在 ...

策略报告 | 投资策略 自主可控的第一个逻辑是国家政策多年布局下的积累，顶层设计重视，现代 化产业体系建设要求固链、补链、延链，顶层设计对自主可控领域重视程度 高；自主可控的第二个逻辑是国产替代，即中国对美反制措施可能推升中国 对美进口商品价格，导致对美依赖度较高的商品种类出现供给缺口，国内供 给端替代供给缺口下相关板块有望看到盈利驱动下的业绩改善。 穿透到二级行业，短期可以关注估值处于低位的方向，中期关注产业节奏。 估值方面，前期估值处于低位的板块主要为军工、医药、电子。 产业趋势投资涵盖三个阶段，当前自主可控多数子板块位于阶段一的尾声。 如何能够迈向阶段二开启双击行情？先看产能周期后看业绩，即标的是否开 启大额资本开支以形成产业链的完善可以作为是否进入阶段二的判断，业绩 大面积改善可以作为阶段二拐点出现的确认。 从这个角度，我们判断自主可控各板块产业节奏：军工→信创→医药→先进 制造。 行业比较周报 证券研究报告 中美会谈下，自主可控板块的节奏与机会 核心结论：6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实 事求是看待取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访 华。双方经贸协 ...

Investment Rating - The report gives a "Buy" rating for the company with a target price of 45.2 CNY, compared to the current price of 36.35 CNY [6]. Core Insights - The company, TaiLing Microelectronics, is a leader in wireless IoT SoC, focusing on cutting-edge technology and binding with industry-leading clients. It has a strong market position in multiple protocol technologies, including low-power Bluetooth and Zigbee [1][3]. - The company has shown significant growth in recent financial performance, with a projected revenue of 844 million CNY in 2024, representing a year-over-year increase of 32.69%, and a net profit of 97.41 million CNY, up 95.71% year-over-year [2][24]. - The company is actively investing in R&D, with R&D expenses reaching 220 million CNY in 2024, accounting for 26.06% of revenue, and a total of 531 million CNY invested over the past three years [2][41]. Summary by Sections Company Overview - TaiLing Microelectronics, established in June 2010, specializes in the R&D, design, and sales of wireless IoT system-level chips, becoming a representative enterprise in the field with a comprehensive product range [1][13]. Financial Analysis - The company's revenue is primarily driven by IoT chips, which are expected to generate 765 million CNY in 2024, a 31.53% increase year-over-year. Audio chips are also experiencing rapid growth, with projected revenue of 76 million CNY, up 61.98% year-over-year [24][26]. - The company has achieved a gross margin of 48.34% in 2025, with IoT chip margins at 47.17% and audio chip margins significantly higher at 58.36% [28][41]. R&D Analysis - The company emphasizes R&D as a driver of growth, with a focus on developing new technologies and products, including the launch of AI chips and advancements in low-power wireless communication standards [35][38]. - In 2024, the company introduced the TL721X series AI chips and the TLEdgeAI-DK development platform, marking its entry into the AIoT era [4][36]. Industry Analysis - The global SoC market is projected to reach approximately 186.48 billion USD by 2025, with a compound annual growth rate of 8.01% from 2025 to 2030 [43][44]. - The low-power Bluetooth chip market is expected to grow from 3.36 billion USD in 2023 to 8.59 billion USD by 2032, indicating a robust demand for wireless communication technologies [48][52].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovation-driven pharmaceutical enterprise, focusing on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It is projected to achieve a revenue of HKD 12.26 billion in 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with a strong pipeline that is expected to drive future growth. The sales of innovative drugs are anticipated to continue increasing, with a projected revenue of HKD 9.477 billion in 2024, marking a 38.1% year-on-year growth [16][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system, employing over 1,800 professionals and creating several national-level research institutions. It has been recognized as a key high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethylnitro (甲磺酸氟马替尼片), which are expected to contribute significantly to revenue growth [16][17]. 2. Market Performance - The sales of Amelotin, the first domestic third-generation EGFR TKI, are projected to grow rapidly, with a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales of third-generation EGFR TKIs by 2024 [2]. - The company has also seen significant sales growth in Fluoromethylnitro, with a 54% increase in 2023 and a projected 36% growth in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence through collaborations, such as granting global exclusive licensing rights for HS-10535 to Merck, indicating strong potential for future revenue streams [4][5]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion, respectively, with net profits expected to reach HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 45.2 CNY, compared to the current price of 36.35 CNY [6]. Core Insights - The company, TaiLing Microelectronics, is a leader in wireless IoT SoC, focusing on cutting-edge technology and binding with industry-leading clients. It has a strong market position in multiple protocol technologies, including low-power Bluetooth and Zigbee [1][3]. - The company has shown significant growth in recent financial performance, with a projected revenue of 844 million CNY in 2024, representing a year-on-year increase of 32.69%, and a net profit of 97.41 million CNY, up 95.71% year-on-year [2][24]. - The company is heavily investing in R&D, with R&D expenses reaching 220 million CNY in 2024, accounting for 26.06% of revenue, and a total of 531 million CNY invested over the past three years [2][41]. Summary by Sections Company Overview - TaiLing Microelectronics, established in June 2010, specializes in the R&D, design, and sales of wireless IoT system-level chips, becoming a representative enterprise in the field with a comprehensive product range [1][13]. Financial Analysis - The company's revenue is primarily driven by IoT chips, which are expected to generate 765 million CNY in 2024, a 31.53% increase year-on-year. Audio chips are also experiencing rapid growth, with projected revenue of 76 million CNY, up 61.98% year-on-year [24][26]. - The company has achieved a gross margin of 48.34% in 2025, with IoT chip margins at 47.17% and audio chip margins significantly higher at 58.36% [28][41]. R&D Analysis - The company emphasizes R&D-driven growth, with a focus on developing new technologies and products, including the launch of AI chips and advancements in low-power wireless communication standards [35][36]. - In 2024, the company introduced the TL721X series AI chips and the TLEdgeAI-DK development platform, marking its entry into the AIoT era [4][36]. Industry Analysis - The global SoC market is projected to reach approximately 186.48 billion USD by 2025, with a compound annual growth rate of 8.01% from 2025 to 2030 [43]. - The low-power Bluetooth chip market is expected to grow from 3.36 billion USD in 2023 to 8.59 billion USD by 2032, indicating a robust demand for wireless communication technologies [48][52].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovative pharmaceutical enterprise with a focus on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It has shown robust performance with a projected revenue of HKD 12.26 billion for 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with significant sales growth in its key products, particularly in the oncology sector, which is expected to account for 66.24% of total revenue by 2024 [17][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system with over 1,800 professional researchers, focusing on drug discovery and clinical research. It has been recognized as a national high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethine (甲磺酸氟马替尼片), which have shown strong sales performance [16][17]. 2. Sales Performance - The sales of Amelotin are projected to grow at a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales for third-generation EGFR TKIs by 2024 [2]. - The sales of Fluoromethine increased by 54% in 2023 compared to the previous year, with a projected growth of 36% in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence with global licensing agreements for its innovative drugs, indicating strong potential for future revenue growth [4][5]. 4. Financial Forecast - The revenue forecast for the company is set at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion for the years 2025, 2026, and 2027, respectively, with net profits projected at HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].